icosapent ethyl + atorvastatin

AM240 (also known as AMR102) is a fixed-dose combination drug candidate developed by Amarin Corporation. It consists of icosapent ethyl, a high-purity ethyl ester of eicosapentaenoic acid (EPA), and atorvastatin, a HMG-CoA reductase inhibitor (statin). The "MCR" designation likely refers to a modified-release or multi-component release formulation designed to optimize the delivery of both active ingredients. Icosapent ethyl works by reducing hepatic very-low-density lipoprotein cholesterol (VLDL-C) synthesis and enhancing triglyceride clearance from circulating VLDL particles, while atorvastatin inhibits the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing low-density lipoprotein cholesterol (LDL-C). The combination is intended for the treatment of patients with mixed dyslipidemia, aiming to simultaneously manage elevated triglyceride levels and LDL cholesterol to reduce overall cardiovascular risk.

Other names

icosapent ethyl + atorvastatin combinationAM240 MCRAM-240 MCRAM 240 MCR